
zzso zzso zzso zzso zzso therapies increase the risk of cognitive impairment in women aged 65 years or older and are associated with smaller regional brain zzso however, the link between these two phenomena has not been zzso 

zzso magnetic resonance imaging was performed on zzso women, zzso years after they had participated in zzso zzso clinical trials of zzso zzso Women included in this report were aged zzso years and free of zzso and mild cognitive impairment zzso when originally enrolled in the trials, which lasted an average of 4-6 years and were conducted at 14 academic zzso medical zzso The associations that regional brain volumes and zzso zzso volumes had with the development of cognitive impairment zzso zzso or zzso were contrasted between treatment groups using analyses of zzso 

zzso women developed zzso or probable zzso during zzso Among women who had been prescribed zzso therapies, cognitive impairment was associated with relatively smaller zzso zzso zzso zzso and total brain volumes zzso zzso zzso zzso these associations appeared to be independent of their level of zzso cognitive zzso Among women who had been prescribed zzso these relationships were not zzso instead, cognitive impairment was associated with greater zzso zzso volume in the frontal lobe zzso zzso zzso and overall zzso zzso zzso 

A mechanism by which zzso zzso hormone therapy zzso cognitive impairment appears to be through increased brain zzso 

